Red eye

Greg Gutfeld Signs Multi-Year Contract Extension With FOX News Media

Retrieved on: 
Thursday, April 4, 2024
Communications, Media, General Entertainment, Entertainment, TV and Radio, Fox, Fox Business, Fox Weather, Gutfeld!, MSNBC, The New York Times, The Late Show, FOX, FNC, Fox News, Late Night, CNN, Greg Gutfeld, News, University, Humour, Weather, Fox Corporation, The Tonight Show, FBN, The Daily Show, Red eye, Fox Nation, Comedy, Television

FOX News Media and Greg Gutfeld have agreed to a multi-year contract extension where he will continue as host of FOX News Channel’s (FNC) late-night sensation Gutfeld!

Key Points: 
  • FOX News Media and Greg Gutfeld have agreed to a multi-year contract extension where he will continue as host of FOX News Channel’s (FNC) late-night sensation Gutfeld!
  • Previously, Gutfeld was the host of The Greg Gutfeld Show (2015-2021), which aired on Saturday nights and outpaced several late-night broadcast programs in viewership.
  • FOX News Media operates the FOX News Channel (FNC), FOX Business Network (FBN), FOX News Digital, FOX News Audio, FOX News Books, the direct-to-consumer streaming services FOX Nation and FOX News International and the free ad-supported television service FOX Weather.
  • Owned by Fox Corporation, FOX News Media reaches nearly 200 million people each month.

XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

Retrieved on: 
Thursday, February 8, 2024
Q&A, Red eye

HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.

Key Points: 
  • HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
  • XNK's presentation starts at 10:45 CET.
  • The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye's homepage.
  • XNK's presentation will be followed by a short Q&A session.

XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

Retrieved on: 
Thursday, February 8, 2024
Q&A, Red eye

HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.

Key Points: 
  • HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
  • XNK's presentation starts at 10:45 CET.
  • The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye's homepage.
  • XNK's presentation will be followed by a short Q&A session.

Medivir to present at the Redeye Life Science Day

Retrieved on: 
Wednesday, November 22, 2023
Nasdaq Stockholm, Drug development, CET, Patient, Partnership, Market capitalization, Cancer, Red eye, SMAC, Pharmaceutical industry, Medivir

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.

Key Points: 
  • STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.
  • CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Hennessey's 1,000-HP 'Last Stand' models celebrate the end of the Hellcat-powered Dodge SRT Challenger and Charger

Retrieved on: 
Tuesday, November 7, 2023
Prison escape, Challenger, Plaque, Gasoline, SRT, Carbon, Last, Calibration, Torque, Last stand, Hennessey, Charger, Dodge, HEMI, Hellcat, Red eye

SEALY, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Hennessey, the Texas-based hypercar manufacturer, and high-performance vehicle creator, celebrates the nine-year run of the supercharged 6.2-liter Hellcat HEMI V8 with limited edition 'Last Stand' models of the popular Dodge SRT Challenger and Charger models.

Key Points: 
  • That's only 25 horsepower shy of the automaker's flagship SRT Demon 170 — and the Hennessey H1000 ‘Last Stand' editions run on pump-unleaded gasoline.
  • John Hennessey, company founder and CEO: "The Challenger and Charger are two of our most popular models, with monstrous horsepower in a comfortable and capable chassis.
  • The H1000 'Last Stand' upgrade is available on 2021-2023 Dodge SRT Challenger and Charger models.
  • It may be ordered through authorized Hennessey Performance Dodge dealers or Hennessey directly through HennesseyPerformance.com or by calling +1 979.885.1300.

H.Spectrum+ Funding Bold New Ideas Worldwide for Disruption in Health Tech

Retrieved on: 
Thursday, June 1, 2023
Food safety, Silicon Valley Bank, Red eye, Organization, Silicon, MRI, FTC, Medicine, AI, Alzheimer's disease, FDA, Magnetic resonance imaging, Nursing, Renewable energy, Medical device, EU

TAIPEI, June 1, 2023 /PRNewswire/ -- H.Spectrum+, a leading APAC health tech startup accelerator, today announced the final month of its 2023 open call for proposals, which focuses not only on startup organizations but also on medical students and healthcare practitioners with creative ideas in their field. Backed by Foxconn Technology Co. Ltd. (FTC) and Yonglin Foundation , the organization has greatly expanded their focus post-pandemic and has set its sights on disrupting biotech, AI, and smart healthcare through global partnerships.

Key Points: 
  • To submit an innovative idea or learn more, please visit: https://docs.google.com/forms/d/e/1FAIpQLSeefgf6_W-FlD3lkfomPXZkfl4JvJi1...
    In the wake of the collapse of Silicon Valley Bank, which the life sciences and healthcare industries relied on heavily, a gap in funding opportunities has left health tech startups struggling to secure capital.
  • While long-term prospects for health tech are trending up according to the accounting firm Deloitte , particularly in the UK , such challenges could lead organizations to increasingly seek support from other sources outside of the financial industry.
  • As the health tech and biotech industries in Taiwan continue to expand, entrepreneurs and startups face growing cost-related challenges, particularly with inflation on the rise globally.
  • One of H.Spectrum+'s success stories is Redeye Biomedical , a startup that specializes in optical detection techniques across smart health, food safety, and environmental protection.

H.Spectrum+ Funding Bold New Ideas Worldwide for Disruption in Health Tech

Retrieved on: 
Thursday, June 1, 2023
Food safety, Silicon Valley Bank, Red eye, Organization, Silicon, MRI, FTC, Medicine, AI, Alzheimer's disease, FDA, Magnetic resonance imaging, Nursing, Renewable energy, Medical device, EU

TAIPEI, June 1, 2023 /PRNewswire/ -- H.Spectrum+, a leading APAC health tech startup accelerator, today announced the final month of its 2023 open call for proposals, which focuses not only on startup organizations but also on medical students and healthcare practitioners with creative ideas in their field. Backed by Foxconn Technology Co. Ltd. (FTC) and Yonglin Foundation , the organization has greatly expanded their focus post-pandemic and has set its sights on disrupting biotech, AI, and smart healthcare through global partnerships.

Key Points: 
  • To submit an innovative idea or learn more, please visit: https://docs.google.com/forms/d/e/1FAIpQLSeefgf6_W-FlD3lkfomPXZkfl4JvJi1...
    In the wake of the collapse of Silicon Valley Bank, which the life sciences and healthcare industries relied on heavily, a gap in funding opportunities has left health tech startups struggling to secure capital.
  • While long-term prospects for health tech are trending up according to the accounting firm Deloitte , particularly in the UK , such challenges could lead organizations to increasingly seek support from other sources outside of the financial industry.
  • As the health tech and biotech industries in Taiwan continue to expand, entrepreneurs and startups face growing cost-related challenges, particularly with inflation on the rise globally.
  • One of H.Spectrum+'s success stories is Redeye Biomedical , a startup that specializes in optical detection techniques across smart health, food safety, and environmental protection.

Co-founder Per Nordling presents Partinc at Redeye SaaS Day, May 16, 2023

Retrieved on: 
Monday, May 15, 2023
Software as a service, CET, Red eye, Nordling, Software

STOCKHOLM, May 15, 2023 /PRNewswire/ -- Tomorrow, Partinc's co-founder and partner Per Nordling will take part at Redeye's SaaS Day, to present Partinc's investment strategies, portfolio companies and deal sourcing activities.

Key Points: 
  • STOCKHOLM, May 15, 2023 /PRNewswire/ -- Tomorrow, Partinc's co-founder and partner Per Nordling will take part at Redeye's SaaS Day, to present Partinc's investment strategies, portfolio companies and deal sourcing activities.
  • The presentation will be held at 11.20 on May 16, 2023, and will be available for online streaming and recorded for distribution purposes.
  • The SaaS Day is an annual event hosted by Redeye and this year in total 16 companies from the industry have been invited to present and participate in panel debates.
  • The event can be viewed at:
    between 9.00 am and 3.30 pm CET on May 16.

Implantica presents at Redeye Future of Healthcare Seminar

Retrieved on: 
Wednesday, March 29, 2023
Certification, Red eye, CET

VADUZ, Liechtenstein, March 29, 2023 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, announces that on Thursday, March 30, at 14:45, Peter Forsell presents Implantica and it's latest developments at Redeye's Future of Healthcare Seminar.

Key Points: 
  • VADUZ, Liechtenstein, March 29, 2023 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, announces that on Thursday, March 30, at 14:45, Peter Forsell presents Implantica and it's latest developments at Redeye's Future of Healthcare Seminar.
  • The presentation will be live broadcasted in English and can be followed at: https://www.redeye.se/events/870753/redeye-future-of-healthcare-event where the replay and the presentation will be available afterwards.
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
  • The company's Certified Adviser is FNCA Sweden AB, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on March 29, 2023, at 8:30 a.m. CET.

XNK Therapeutics to present at Redeye's Regenerative Medicine/Cell Therapy event on February 22

Retrieved on: 
Tuesday, February 21, 2023
CET, Red eye, Cancer, Pharmaceutical industry

HUDDINGE, Sweden, Feb. 21, 2023 /PRNewswire/ -- XNK Therapeutics AB's CEO Johan Liwing will present at Redeye's Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.

Key Points: 
  • HUDDINGE, Sweden, Feb. 21, 2023 /PRNewswire/ -- XNK Therapeutics AB's CEO Johan Liwing will present at Redeye's Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.
  • XNK's presentation starts at 09:10 and is followed at 09:55 by a panel discussion regarding cell therapy for cancer.
  • The presentation is broadcasted live starting at 09:00 and can be followed at: https://www.redeye.se/events/868745/redeye-theme-regenerative-medicine-c...